Multiple myeloma patients treated with BCMA-directed CAR T-cell therapy have high response rate
Published: 7 Dec 2019
Views: 444
Prof Deepu Madduri - Mount Sinai, New York, USA
Prof Deepu Madduri presents data from the CARTITUDE-1 study during a press conference at the ASH 2019 meeting.
The study evaluated the response rate of JNJ-4528, a CAR-T Cell Therapy directed against B-Cell maturation antigen (BCMA), in multiple myeloma patients.
Read more about the study here.
Watch our interview with Prof Deepu Madduri here.
- Categories:
- Haematology oncology
- Antibodies & immunotherapy
Related Videos
Are remissions for AML patients 'better' after daunorubicin and cytarabine lipos...
Prof Daniel Ryan - University of Rochester, Rochester, USA
24 Dec 2019
Is enasidenib plus azacitidine better than with azacitidine alone for AML patien...
Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA
24 Dec 2019
PET-Directed therapy for early-stage diffuse large B-cell lymphoma
Prof Daniel Persky - University of Arizona Cancer Center, Tucson, USA
24 Dec 2019
Lenalidomide maintenance for transplant eligible and transplant ineligible newly...
Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK
24 Dec 2019
Dasatinib vs imatinib in the treatment of paediatric ALL
Dr Shuhong Shen - National Children's Medical Center, Shanghai, China
24 Dec 2019
LYRA: Maintenance therapy with daratumumab improves depth of response and achiev...
Dr Robert Rifkin - Rocky Mountain Cancer Centers, Denver, USA
17 Dec 2019
ELEVATE TN: Comparing acalabrutinib monotherapy or in combination with obinutuzu...
Dr Jeff Sharman - Willamette Valley Cancer Institute and Research Center, Eugene...
17 Dec 2019
Complete remission after induction chemotherapy determines clinical efficacy of ...
Prof Kristoffer Hellstrand - University of Gothenburg, Gothenburg, Sweden
17 Dec 2019
Weekly wKRd-D in newly diagnosed multiple myeloma achieves unprecedented results
Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
13 Dec 2019
